Extended and saturation needle biopsy for the diagnosis of prostate cancer

被引：21

作者：

Chrouser K.L. ^{[1
]}

Lieber M.M. ^{[1
]}

机构：

[1] Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN

来源：

Current Urology Reports | 2004年 / 5卷 / 3期

关键词：

Peripheral Zone; Prostate Biopsy; Prostate Cancer; Prostate Needle Biopsy; Sextant Biopsy;

D O I：

10.1007/s11934-004-0041-7

中图分类号：

学科分类号：

摘要：

The diagnosis of prostate cancer hinges on the use of systematic ultrasound-guided transrectal needle biopsy. The choice of technique is important, especially for patients with a history of a negative biopsy. Saturation biopsy can be considered for patients at risk of cancer who are willing to accept the side effects and who understand that clinically insignificant cancers can be detected. For patients with previous negative sextant biopsies, expanding the zones sampled and increasing the number of biopsy cores can help detect significant cancers while they are still confined. However, as extended biopsy becomes more commonly performed for initial diagnosis, there likely will be less need for saturation biopsy protocols. © 2004, Current Science Inc.

引用

页码：226 / 230

页数：4

共 41 条

[1]

Hodge K.K., McNeal J.E., Terris M.K., Stamey T.A., Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate, J Urol, 142, pp. 71-74, (1989)

[2]

Gann P.H., Hennekens C.H., Stampfer M.J., A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer, JAMA, 273, pp. 289-294, (1995)

[3]

Punglia R.S., D'Amico A.V., Catalona W.J., Et al., Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen, N Engl J Med, 349, pp. 335-342, (2003)

[4]

Jain S., Bhojwani A.G., Mellon J.K., Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers, Postgrad Med J, 78, pp. 646-650, (2002)

[5]

Ozen H., Aygun C., Ergen A., Et al., Combined use of prostatespecific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer, Am J Clin Oncol, 24, pp. 610-613, (2001)

[6]

Scherr D.S., Eastham J., Ohori M., Scardino P.T., Prostate biopsy techniques and indications: When, where, and how?, Semin Urol Oncol, 20, pp. 18-31, (2002)

[7]

Garcia-Segura J.M., Sanchez-Chapado M., Ibarburen C., Et al., In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology, Magn Reson Imaging, 17, pp. 755-765, (1999)

[8]

Halpern E.J., Frauscher F., Rosenberg M., Gomella L.G., Directed biopsy during contrast-enhanced sonography of the prostate, AJR Am J Roentgenol, 178, pp. 915-919, (2002)

[9]

Chon C.H., Lai F.C., McNeal J.E., Presti J.C., Use of extended systematic sampling in patients with a prior negative prostate needle biopsy, J Urol, 167, pp. 2457-2460, (2002)

[10]

Presti J.C., Prostate biopsy: How many cores are enough?, Urol Oncol, 21, pp. 135-140, (2003)

← 1 2 3 4 5 →